Supplement
Rapamycin
The most exciting and most serious molecule in longevity.
Rapamycin (sirolimus) inhibits mTOR, a central aging pathway. We grade Rapamycin C on evidence and D for worth-it at about $100+ per month.
Evidence
Worth it
Typical cost: $100+/month
What it does
Rapamycin (sirolimus) inhibits mTOR, a central aging pathway. It extends lifespan in every animal tested, from yeast to mice, which makes it the most credible longevity drug candidate and also a prescription immunosuppressant with real risks.
What the research says
Extends lifespan in laboratory animals
Evidence: strong. Replicated across species; the animal record is exceptional.
Extends human healthspan
Evidence: weak. No human longevity trials completed; off-label use is experimental.
DRAFT: unmatched animal record, zero human longevity data; the grade reflects the human gap, not the animal promise.
Is it worth it?
DRAFT: expensive and prescription-only; you are buying into an experiment, not a result.
Typical cost
$100+/month
Common form, not a brand recommendation
Dosage contextno established dose
Prescription drug. No established dosage for longevity use; off-label protocols are experimental and must be doctor-supervised.
Safety notes
PRESCRIPTION DRUG with serious risks including immune suppression and metabolic effects. Off-label longevity use is experimental and must only happen under a doctor's supervision. Do not self-source. This page is information, not medical advice.
Longevity Lab Report
Rapamycin news, graded when it happens.
New studies, dose debates, and expert shifts on rapamycin, in one email a week. Free.
Changelog
Last updated 2026-10-15
- 2026-10-15|Batch 1 expansion entry, DRAFT. Grades provisional; expert positions unsourced unless noted.
- 2026-10-15|Goals/dosage added; prescription flag set where applicable.